Inducing senescence in cancer cells is an effective approach to suppress cancer growth, and it contributes significantly to the efficacy of therapeutic drugs. Previous studies indicated that transcription factors NF-κB (nuclear factor κ-light-chain-enhancer of activated B cells) and C/EBPβ (CCAAT/enhancer-binding protein-β) play a critical role in the establishment of senescence by upregulating proinflammatory cytokines, notably interleukin-6 (IL-6) and interleukin-8 (IL-8). However, it is not clear how these two factors are activated in response to senescence-inducing stimuli and subsequently regulate gene transcription. Here, we reveal Bcl-2-associated transcription factor 1 (Bclaf1) as a novel player in the therapeutic drug doxorubicin-induced senescence (TIS) in multiple cancer cells. Bclaf1 is upregulated through the ATM/Nemo/NF-κB pathway during TIS and is a direct target of p65 and c-Rel. The induction of Bclaf1 by NF-κB is essential for C/EBPβ upregulation and IL-6/IL-8 transcription during TIS. Bclaf1 can interact with the leucine zipper region of C/EBPβ and cooperate with C/EBPβ to upregulate IL-8. Furthermore, we show that Bclaf1 is required for the effectiveness of doxorubicin (Dox) treatment-induced tumor suppression in a xenograft tumor model. These finding suggest that Bclaf1 plays a crucial role in transducing the senescence-inducing signal from NF-κB to C/EBPβ during TIS, thus amplifying the signals for the establishment of senescence. Given the recent revelation that Bclaf1 is involved in tumorigenesis, our data indicate that the responsiveness of Bclaf1 to NF-κB may determine the effectiveness of therapeutic drugs.
Inducing senescence in cancer cells is an effective approach to suppress cancer growth, and it contributes significantly to the efficacy of therapeutic drugs. Previous studies indicated that transcription factors NF-κB (nuclear factor κ-light-chain-enhancer of activated B cells) and C/EBPβ (CCAAT/enhancer-binding protein-β) play a critical role in the establishment of senescence by upregulating proinflammatory cytokines, notably interleukin-6 (IL-6) and interleukin-8 (IL-8). However, it is not clear how these two factors are activated in response to senescence-inducing stimuli and subsequently regulate gene transcription. Here, we reveal Bcl-2-associated transcription factor 1 (Bclaf1) as a novel player in the therapeutic drug doxorubicin-induced senescence (TIS) in multiple cancer cells. Bclaf1 is upregulated through the ATM/Nemo/NF-κB pathway during TIS and is a direct target of p65 and c-Rel. The induction of Bclaf1 by NF-κB is essential for C/EBPβ upregulation and IL-6/IL-8 transcription during TIS. Bclaf1 can interact with the leucine zipper region of C/EBPβ and cooperate with C/EBPβ to upregulate IL-8. Furthermore, we show that Bclaf1 is required for the effectiveness of doxorubicin (Dox) treatment-induced tumor suppression in a xenograft tumor model. These finding suggest that Bclaf1 plays a crucial role in transducing the senescence-inducing signal from NF-κB to C/EBPβ during TIS, thus amplifying the signals for the establishment of senescence. Given the recent revelation that Bclaf1 is involved in tumorigenesis, our data indicate that the responsiveness of Bclaf1 to NF-κB may determine the effectiveness of therapeutic drugs. Cellular senescence is a protective cellular response to a variety of external and internal stresses and serves to prevent damaged cells from proliferating. 1 The types of stresses include but are not limited to telomere attrition, 2 excessive mitogenic stimulation 3 and DNA damage. 4 Accumulative evidence supports the notion that cellular senescence physiologically functions as an essential tumor suppression mechanism especially at the premalignant stage. 5, 6 Numerous chemotherapeutic agents, including the commonly used chemotherapeutic agent doxorubicin (Dox), induce senescence in cancer cells, 7 significantly contributing to their effectiveness. We refer to therapeutic drug doxorubicininduced senescence as TIS.
A key feature of cellular senescence is stable cell cycle arrest that is often executed by the p53 and Rb tumor suppressor pathways. 3, 8 Senescent cells also display other features such as an increased senescence-associated galactosidase (SA-β-gal) activity 9 and the secretion of various factors including chemokines and cytokines. 10, 11 The latter phenomenon is referred to as senescence-associated secretory phenotype (SASP), and this process may contribute to the elimination of senescent cells by immune cells in vivo. 6 Although SASP was initially considered a hallmark of senescence, it has become clear that numerous SASP components, such as interleukin-6 (IL-6) and interleukin-8 , are produced at the early stage of the senescent process and actively promote the initiation and reinforcement of senescence. [12] [13] [14] In addition, during the course of cellular senescence, cells undergo massive changes in gene expression profiles, collectively leading to the establishment of the senescence program that includes SASP. 11, 15 Recent studies suggest that the transcriptional factors NF-κB (nuclear factor κ-light-chain-enhancer of activated B cells) and C/EBPβ (CCAAT/enhancer-binding protein-β), which are critically involved in cytokine production in immune response, play a prominent role in gene regulation associated with the induction of SASP and senescence. 12, 15, 16 However, the mechanism by which these two factors are activated in response to senescence-inducing stimuli and subsequently induce transcriptional changes in senescence remains unclear.
A persistent DNA damage response (DDR) appears to be a pivotal trigger for cellular senescence. 4 It is also the key mechanism of many cancer therapeutic drugs. DNA damage foci and activation of the key components of DDR are often observed in cells undergoing senescence induced by various stresses. 4 ,10 DDR induces cell cycle arrest through the p53/p21 and Rb/p16 pathways 17, 18 and is essential for SASP induction typically with the involvement of DDR components, such as ataxia telangiectasia mutated protein (ATM), checkpoint kinase 2 (CHK2) and NBS. 4, 16 However, the critical players and exact pathways linking DDR to NF-κB and C/EBPβ as well as SASP have not been well defined.
Bclaf1 (Bcl-2-associated transcription factor1) was first identified in a yeast two-hybrid screen as a binding protein for the adenoviral Bcl2 homolog E1B19K. 19 Bclaf1 knockout mice are embryonic lethal because of defects in lung development. 20 Ectopical Bclaf1 expression induces apoptosis in various cell types or autophagic cell death in myeloma cells. 19, 21 However, thymocytes and splenocytes isolated from Bclaf1 knockout mice exhibit normal responsiveness to various apoptotic stimulations, thus arguing its role in apoptosis at physiological levels. 20 The Bclaf1 protein contains homologies to the basic zipper (bZIP) and Myb DNA-binding domain and can bind to DNA. 19 Several studies suggested a role of Bclaf1 in DDR. Bclaf1 promotes TP53 gene transcription through interaction with PKCδ in response to DNA damage 22, 23 and interacts with γ-H2AX in response to ionizing radiation. 24 Although most of studies suggest that Bclaf1 is a tumor suppressor, a recent report indicated that Bclaf1 was oncogenic in colorectal cancers. 25 Thus, the function of Bclaf1 in carcinogenesis is controversial.
Here, we report that Bclaf1 is an important player in TIS in multiple cancer cells. We provide evidence to suggest that NF-κB is activated by the ATM/NF-κB essential modulator (Nemo) axis and that Bclaf1 is a downstream gene of NF-κB that is required for C/EBPβ upregulation and cooperates with C/EBPβ to regulate transcription of SASP components.
Results

Bclaf1 is involved in TIS in multiple cancer cells.
Senescence is an important mechanism contributing to the effectiveness of DNA damage-based chemotherapies. 26, 27 In an effort to understand the underlying molecular mechanism, we chronically treated MCF-7 breast cancer cells as well as HCT116 and HT-29 colon carcinoma cells with low concentrations of Dox that induces DNA double-strand breaks. 28 As reported previously, 7 Figure S1D) , supporting the role of Bclaf1 in TIS. However, these data also suggest that Bclaf1 may play a different role in unstressed cells.
DNA damage-mediated Bclaf1 upregulation is dependent on ATM/ATR and Nemo. To delineate the pathways involved in Bclaf1 upregulation, we first individually knocked down ATM and ATR (ataxia telangiectasia and rad3 related) using their respective siRNAs. ATM and ATR are central kinases in the signaling cascade of DDR. 29 As expected, on day 3 of treatment, DNA damage-induced phosphorylation of the effector kinases checkpoint kinase 1 (Chk1) and Chk2 was diminished upon knockdown of either ATM or ATR (Figure 2a) . Not surprisingly, Bclaf1 upregulation was also abolished at both protein and mRNA levels (Figure 2a and Supplementary  Figure S2A ), suggesting that Bclaf1 is upregulated in response to DDR. Accordingly, the reduction in senescence resulting from ATM or ATR knockdown was not further enhanced upon simultaneous knockdown of Bclaf1 (Figure 2b) , confirming that the action of Bclaf1 is downstream of ATM/ATR. Although p53 is a downstream effector in DDR and critically involved in senescence, Bclaf1 was upregulated by Dox in p53-deficient HCT116 cells but to a lesser extent (Supplementary Figures  S2B and C) . Although this result cannot exclude the involvement of p53, it suggests that other transcription factors play a role in this process.
Given that NF-κB is a master regulator of gene transcription associated with SASP and senescence, we hypothesize that it may upregulate Bclaf1. To examine this hypothesis, we knocked down Nemo using a specific siRNA given that Nemo is the critical link between ATM and NF-κB activation in other scenarios of DDR. 30 Nemo depletion inhibited Dox-induced nuclear translocation of p65 and c-Rel (Figure 2e ), a critical event in NF-κB activation. Bclaf1 upregulation was also abrogated (Figure 2c and Supplementary Figure S2D) . Moreover, compared with the control siRNA-transfected cells, fewer senescent and more proliferative cells, which were measured by Ki67 staining, were observed in Nemo or Bclaf1 siRNA-transfected cells after Dox treatment. However no additive effects were observed when Bclaf1 and Nemo were simultaneously knocked down (Figure 2d and Supplementary Figure S3 ). These results indicate that Bclaf1 upregulation occurs downstream of the ATM/Nemo axis.
Bclaf1 is a direct target of NF-κB. To directly investigate whether Bclaf1 is regulated by NF-κB, we transfected each individual member of NF-κB into 293T cells and found that p65 and c-Rel increased the endogenous expression of Bclaf1 (Figure 3a) . To confirm this finding, we transfected siRNAs against p65 and c-Rel either alone or together into HCT116 cells before Dox treatment. As expected, induction of Bclaf1 expression by DNA damage was partially inhibited by downregulation of either p65 or c-Rel, and a more complete inhibition was observed when both proteins were downregulated (Figure 3b and Supplementary Figure S2E) . In addition, similar phenotype was also observed in HCT116 p53
− / − cells, despite that depletion of both p65 and c-Rel did not further enhance this impact (Supplementary Figure S2F) To investigate whether Bclaf1 was directly regulated by NF-κB, we analyzed the promoter region of human Bclaf1 and identified a potential NF-κB-binding consensus sequence as indicated (Figure 3c ). We fused this region upstream of a luciferase reporter gene. Co-transfection of p65 with the reporter stimulated the luciferase activity (Figure 3d ),
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A Shao et al indicating that Bclaf1 is a target of NF-κB. To further confirm this finding, we performed chromatin immunoprecipitation (ChIP) assays using p65-or c-Rel-specific antibodies in both untreated and Dox-treated cells. The results suggested that the binding of p65 to the potential NF-κB-binding region within the Bclaf1 promoter is induced by Dox treatment, whereas the binding of c-Rel is constitutive ( Figure 3e ). Taken together, these data demonstrated that p65 and c-Rel are bound to the Bclaf1 promoter and transcriptionally activate Bclaf1 during TIS.
Bclaf1 is required for C/EBPβ upregulation during TIS. C/EBPβ is another important transcription factor for the establishment of the SASP. C/EBPβ works synergistically with NF-κB to induce transcription of various cytokines including IL-6 and IL-8. Figures S4A and B) . The induction of p15, a downstream target of C/EBPβ and inhibitor of cell cycle, 13 by Dox treatment was also reduced upon Bclaf1 knockdown, whereas inductions of other cell cycle inhibitors p21 and p27 as well as p53 and p53 downstream genes were not affected ( Figure 4b and Supplementary Figure S5B) . However, p16 was not detected in HCT116 and HT-29 cells (Figure 4b and Supplementary Figure S5B ), probably because of epigenetic silencing by methylation that occurs in the promoter region of p16 as previously reported. 31 These results suggest that Bclaf1 may mediate C/EBPβ upregulation by NF-κB.
To prove this hypothesis, we co-transfected the Bclaf1 expression plasmid with Nemo siRNA into HCT116 cells and treated these cells with Dox. Nemo knockdown suppressed C/EBPβ and Bclaf1 upregulation (Figure 4a ). However, forced expression of Bclaf1 restored C/EBPβ upregulation, whereas the Myb deletion mutant did not (Figure 4c ). These results indicate that Bclaf1 is required for C/EBPβ upregulation during TIS and its Myb domain may play a role in this process.
We next examined the effect of Bclaf1 overexpression on C/EBPβ. Despite causing mild cell death, Bclaf1 overexpression in HCT116 increased C/EBPβ mRNA and protein expression at 72 h, confirming that Bclaf1 upregulation induces C/EBPβ expression (Figures 4d and e) . To explore the mechanisms by which Bclaf1 upregulates C/EBPβ, we performed a ChIP assay to examine whether Bclaf1 binds to the promoter region of the transcriptionally active isoform of C/EBPβ-LAP (liver-enriched transcriptional activator protein). We designed three sets of primers that spanned -15 to -543 bp (Figure 4f , +1 indicates the first bp of exon 1) of the C/EBPβ promoter and demonstrated that Bclaf1 was specifically recruited to the p3 region (Figure 4f ) and the amount was increased after Dox treatment (Supplementary Figure S5D) .
To further examine the functional relationship between Bclaf1 and C/EBPβ in TIS, we knocked down these two proteins individually or in combination and demonstrated that senescence was inhibited by depleting either protein. In addition, no additive effect was observed when both proteins were simultaneously depleted, indicating these two proteins . At 24 h after transfection, the cells were untreated or treated with Dox (50 ng/ml) for 3 days followed by western blot analysis (a and c), or for 7 days followed by SA-β-gal staining and cell counting as described above (b and d). (e) Cells treated as described in (c) were subjected to nuclear-cytoplasm fractionation. β-Tubulin and lamin B were used as cytoplasmic and nuclear loading controls, respectively. **Po0.01 and ***Po0.001
Bclaf1 regulates senescence via C/EBPβ A Shao et al function in the same pathway (Figure 4g ). Taken together, our results suggest that Bclaf1-induced C/EBPβ upregulation is a key event in TIS.
Bclaf1 interacts with C/EBPβ. C/EBPβ is subject to autoregulation driven by homo-or hetero-dimerization with other members of the C/EBPβ family. 32, 33 We therefore examined whether Bclaf1 interacts with C/EBPβ. We untreated or treated HCT116 cells with Dox for 3 days and extracted chromatin-binding proteins for immunoprecipitation. We found C/EBPβ was present in the Bclaf1 immunocomplex in both treated and untreated cells (Figure 5a ). We further determined the regions in both proteins that mediated their interaction via immunoprecipitation of Flag-tagged either Bclaf1 or C/EBPβ and their deletion mutants followed by western blot analysis of the presence of HA-C/EBPβ or endogenous Bclaf1. The results indicated that the leucine zipper region of C/EBPβ (Figure 5c ) and the Myb domain of Bclaf1 (Figure 5b ) are involved in the interaction. In addition, other regions of Bclaf1 also made contributions.
Bclaf1 cooperates with C/EBPβ to upregulate IL-8. Similar to its effect on C/EBPβ, shRNA-mediated Bclaf1 depletion dramatically reduced IL-6 and IL-8 induction by DNA damage at both protein and mRNA levels (Figures 6a-c) . Moreover, Bclaf1 overexpression increased IL-8 transcription in 293T cells (Figure 6d) . We failed to detect IL-6 mRNA probably because IL-6 is not transcribed in 293T cells. To examine whether C/EBPβ plays a role in Bclaf1-mediated IL-8 upregulation, we depleted C/EBPβ before Bclaf1 transfection and demonstrated that IL-8 upregulation is abolished upon C/EBPβ knockdown (Figure 6d ). These results suggest that Bclaf1-induced transcription of some of the NF-κB downstream genes, such as IL-8, is mediated by C/EBPβ. To confirm this finding, we cloned the − 764 to +1 region of the IL-8 promoter (Figure 6e ) and fused it with a luciferase reporter. Consistent with the mRNA data, Bclaf1 overexpression increased IL-8 reporter activity in a C/EBPβ-dependent manner (Figure 6g) .
We next examined whether C/EBPβ recruited Bclaf1 to the IL-6 and IL-8 promoters. ChIP assays indicated Dox treatment increased amounts of Bclaf1 bound to the promoter regions of IL-6 and IL-8 that harbor C/EBPβ-binding motifs (Figure 6f and HCT116 cells untreated or treated with Dox for 3 days were subject to ChIP analysis using anti-p65, anti-c-Rel and control IgG antibodies for immunoprecipitation followed by PCR analysis of promoter regions. ***Po0.001
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Supplementary Figure S5D ). This binding is indeed mediated by C/EBPβ given that C/EBPβ depletion greatly reduced promoter occupancy by Bclaf1 (Figure 6h ). Examination of whether the recruitment of Bclaf1 to the p3 region of C/EBPβ is dependent on C/EBPβ (Figure 6h) showed that in contrast to the IL-6 and IL-8 promoters, Bclaf1 binding to the C/EBPβ promoter was not affected by C/EBPβ knockdown.
Bclaf1 knockdown reduces the efficiency of Dox-induced inhibition of tumor growth in a HT-29 colon cancer xenograft model in vivo. To determine whether Bclaf1 contributes to drug efficiency in vivo, we used an HT-29 colon cancer xenograft model. HT-29 cells expressing the control or shBclaf1 were subcutaneously inoculated into athymic nude mice. Mice were randomly divided into two groups 7 days after inoculation. One group was treated with Dox (3 mg/kg) intraperitoneally every 2 days for 2 weeks and the other group with the carrier PBS. After 4 weeks, the mice were killed and the tumors were harvested and analyzed. Evaluation of tumor sizes and weights indicated that Bclaf1 knockdown did not affect tumor growth, but dramatically reduced the responsiveness of the tumors to Dox treatment 
Discussion
Persistent DDR is a hallmark of senescence that continuously fires the upstream signals characterized by activation of ATM/ATR and other proteins and eventually induces cellular senescence; 4 however, the signaling pathways and critical players connecting DDR signaling to senescence are not well characterized. In this study, we identified Bclaf1 as a critical player in DNA damage-induced senescence by stimulating C/EBPβ upregulation and activities downstream of NF-κB. Bclaf1 depletion impaired the upregulation of IL-6 and IL-8 as well as p15 and senescence likely through C/EBPβ (Figure 7e ). Thus, Bclaf1 is an important regulator for the development of the SASP. It may also contribute to Dox-induced cell cycle arrest via p15.
NF-κB and C/EBPβ are important transcription factors for the upregulation of various nonsecreted and secreted factors required for the development of SASP and senescence. 11, 12 These two proteins are often upregulated and activated and cooperatively induce the transcriptions of the SASP components during senescence. 15, 34 C/EBPβ upregulation is observed following NF-κB activation (Supplementary Figure S5A) . However, the mechanism by which NF-κB activation leads to C/EBPβ upregulation is unclear. We demonstrated that Bclaf1 is the critical mediator between NF-κB and C/EBPβ upregulation. Bclaf1 knockdown severely impaired C/EBPβ upregulation without affecting NF-κB activation (Figure 4b and Supplementary Figures S4 and S5B) , and forced expression of exogenous Bclaf1 restored C/EBPβ upregulation in Nemo knockdown cells (Figure 4c ). Our data indicate that Bclaf1 is required and NF-κB activation alone is not sufficient for C/EBPβ upregulation. ChIP assays revealed that Bclaf1 bound to a region of the C/EBPβ promoter (Figure 4f and Supplementary Figure S5D ) that does not contain any defined transcription factor-binding elements. A previous study demonstrated that Bclaf1 interacts with the p53 promoter region and promotes its transcription. 22 Thus, Bclaf1 may function as a transcriptional activator to promote C/EBPβ upregulation.
IL-6 and IL-8 play pivotal roles in the development of SASP and senescence that are co-regulated by NF-κB and 12, 13 We demonstrated that Bclaf1 was recruited to the IL-6 and IL-8 promoters (Figure 6f and Supplementary Figure S5D ) in a C/EBPβ-dependent manner (Figure 6h ) and cooperates with C/EBPβ to enhance IL-8 transcription (Figures 6d and g ). Thus, Bclaf1 may not only mediate C/EBPβ upregulation but also influence its ability to transactivate IL-6 and IL-8.
Bclaf1 may also play a role in Dox-induced cell cycle arrest through upregulation of p15. Bclaf1 depletion dramatically decreased Dox-induced inhibition of tumor cell growth both in vitro (Figures 1j and k) and in vivo (Figures 7a and b) . Among the cell cycle inhibitors examined, only the upregulation of p15 is suppressed by Bclaf1 knockdown (Figures 4b and 7d and Supplementary Figure S5B) . It has been demonstrated that C/EBPβ is a key transcription factor regulating p15. 13 Thus, Bclaf1 likely regulates p15 through C/EBPβ.
The role of Bclaf1 in transcriptional regulation is poorly understood. Bclaf1 may participate in the epigenetic regulation of chromatin structure as it was found to be associated with L3MBTL3, a member of the malignant brain tumor (MBT) family of chromatin-interacting transcriptional repressors. 35 Recently, Bclaf1 was identified as a component of the RNA splicing complex and regulates the stability of cyclin D and BRCA1 mRNA. 36, 37 Whether this function of Bclaf1 is related to C/EBPβ upregulation requires further investigation.
Bclaf1 responds to NF-κB activation by upregulation. Bclaf1 contains a putative NF-κB-binding element within its promoter. Both ChIP and reporter assays indicate that NF-κB binds to this region and activates Bclaf1 transcription (Figures 3d and e) . Kong et al. 38 have also demonstrated that RelA (p65) binds to the Bclaf1 promoter. However, Bclaf1 upregulation by NF-κB may require its activity to reach a certain threshold. Compared with severe and acute DNA damage treatment, mild DNA damage induces senescence. NF-κB activation is low on day 3 of drug treatment, and a relatively full NF-κB activation was achieved on day 7 as indicated by efficient p65 nuclear translocation and dramatic p65 upregulation (Supplementary Figure S4A) . Thus, NF-κB signaling during DNA damage-induced senescence appears to be a gradual process and subject to further amplification through upregulation. As reported, Nemo can transmit DDR to NF-κB activation; 30 however, it did not mediate NF-κB upregulation (Figure 2e ).
Recent studies have linked Bclaf1 to DDR. Lee et al. 24 reported that Bclaf1 interacted with γH2AX and may regulate the Ku70/DNA-PKcs complex in response to DNA damage. Savage et al. 37 demonstrated that Bclaf1 complexes with BRCA1 and influences the radiosensitivity of cells. We have demonstrated that Bclaf1 is involved in persistent and mild DNA damage-induced senescence downstream of NF-κB activation. Depending on the extent of DNA damage, Bclaf1 probably reacts differently. In the acute DNA damage response, Bclaf1 may be recruited to DNA damage foci and facilitates DNA repair. However, under chronic DNA damage conditions, Bclaf1 expression is upregulated in response to NF-κB activation and subsequently amplifies NF-κB downstream signaling to induce cellular senescence.
Materials and Methods
Plasmids, antibodies and reagents. Full-length Bclaf1 was kindly provided by Dr Tokuko Haraguchi 39 and subcloned into the pRK5 vector with an N-terminal FLAG tag. Bclaf1 and control shRNAs were inserted into the pLKO.1-puro vector. To assess putative NF-κB-binding sites, the following oligo pairs containing four copies of binding sites were used: 5′-CGGGGCTTGCCGGGGCTTGCCGGGGCTTGCCGGGG CTTGCCG-3′ and 5′-AATTCGGCAAGCCCCGGCAAGCCCCGGCAAGCCCCGGCA AGCCCCGGTAC-3′. The annealed oligonucleotide pairs were cloned into the KpnI and EcoRI sites of pBVLuc. 40 The IL-8 promoter sequence flanking the 5′ region from − 764 to +26 was cloned into the pGL3-Basic vector (Promega, Madison, WI, USA).
The following primary antibodies were used for analysis: anti-Bclaf1, anti-p53, antip65, anti-cRel, anti-C/EBPβ and anti-p15 INK4B (Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-phospho-CHK1, anti-phospho-CHK2, anti-Nemo and anti-Ki67 (Cell Signaling Technology, Danvers, MA, USA); and anti-p21 (BD Biosciences, San Jose, CA, USA). Doxorubicin (Sigma, St. Louis, MO, USA) was dissolved in sterile water.
Cells and transfections.
Human colon cancer cells HCT116 and human breast adenocarcinoma cells MCF7 were cultured in medium supplemented with 10% (v/v) FBS. HCT116 cells stably expressing Bclaf1 shRNA were generated by lentiviral infection followed by 2 μg/ml of puromycin selection for 4 days. HCT116 cells were transiently transfected with plasmid DNA using X-tremeGENE HP (Roche, Mannheim, Germany) according to the manufacturer's protocols. SiRNA was transfected into cells using Lipofectamine RNAiMax (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocols. Control siRNA and Bclaf1 siRNA target sequences were designed and synthesized from Genechem (Shanghai, China) as follows: siCtrl, 5′-UUCUCCGAACGUGUCACGU-3′; siBclaf1#1, 5′-GGTTCACTTCGTATCAGAA-3′; siBclaf1#2, 5′-TTCTCAGAATAGTCCAATT-3′. The siRNA target sequences of Atm, Atr, p53, Nemo, p65, c-Rel, and C/EBPβ have been previously reported. [41] [42] [43] [44] [45] [46] [47] Real-time PCR. Total RNA was extracted using TRIzol (Invitrogen) following the manufacturer's protocol. Briefly, 0.8 μg of total RNA from different treatments was reverse transcribed using M-MLV reverse transcriptase (Promega) with an oligo (dT) 18 primer. Real-time PCR was performed using UltraSYBR Mixture (Beijing CoWin Biotech, Beijing, China) and a ViiA 7 real-time PCR system (Applied Biosystems, Foster City, CA, USA). The following primers for Bclaf1 were used: Bclaf1 forward, 5′-CCGCGATTCGGCGTGTCAGG-3′; Bclaf1 reverse, 5′-GACCCAT TTCTTTTCTCCTTGGTT-3′. The primers for IL-6, IL-8 and C/EBPβ have been previously reported. 13 ChIP assay. The ChIP assay was performed using a ChIP-IT Express enzymatic system (Active Motif, Carlsbad, CA, USA) following the manufacturer's instructions. Briefly, HCT116 cells were crosslinked with 1% formaldehyde and neutralized with 0.125 M glycine. Purified chromatin was digested to~500 bp by enzymatic shearing. Anti-Bclaf1, anti-C/EBPβ or control IgG (Santa Cruz) antibodies were used for immunoprecipitation. After reverse crosslinking, DNA samples were analyzed by PCR followed by 2% agarose gel electrophoresis. The PCR primers designed for fragments of the Bclaf1 promoters are as follows: NF-κB forward, 5′-TCACATCTTCCCG CGAGAC-3′ and NF-κB reverse, 5′-CGCTAAATATGCGGGCAAG-3′; NS forward, 5′-ACCAAGCAAAACCAGTCAGGT-3′ and NS reverse, 5′-CGTCTCTTCTAAAAATA CAA-3′. The primers for fragments of the C/EBPβ promoters are as follows: p1 forward, 5′-CCTCTCGCTCCCAATCCC-3′ and p1 reverse, 5′-TCTCCTGAGCCCG GTTATTT-3′; p2 forward, 5′-CTGAAACCTCCGCCTCCTC-3′ and p2 reverse, 5′-GAT TGGGAGCGAGAGGGG-3′; p3 forward, 5′-GTGGGAGTTTACGGGAGGAA-3′ and p3 reverse, 5′-GAGGAGGCGGAGGTTTCAG-3′. Primers for the amplification of C/EBPβ binding sites in the IL-6 and IL-8 promoters have been previously described. 13 Immunoprecipitation and western blot. In total, 5 × 10 6 cells treated with 50 ng/ml doxorubicin for 3 days were lysed in lysis buffer (50 mM Tris-Cl at pH 8.0, 150 mM NaCl, 1% Triton X-100, 1 mM DTT, 1 complete protease inhibitor cocktail tablet and 10% glycerol). Cell lysates were centrifuged at 12 000 r.p.m. for 20 min. The resulting pellets were extracted with lysis buffer containing 500 mM NaCl. After reducing the salt concentration to normal levels (150 mM NaCl) by adding lysis buffer without NaCl, the cell extracts were subjected to immunoprecipitation with 1 μg of Bclaf1 antibody or control IgG plus protein G Sepharose at 4°C overnight. Cell fractionation was performed using Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime Biotechnology, Shanghai, China).
For western blots, cells were either directly lysed in 2 × sodium dodecyl sulfate (SDS) sample buffer or subjected to cytoplasmic/nuclear fractionation. 48 The sliced tumors were minced and lysed in RIPA buffer (0.1% SDS). Subsequent procedures were performed as previously described. 43 SA-β-gal and growth curves. HCT116 or MCF-7 cells were transfected with indicated siRNAs and cultured for 24 h. Subsequently, each group of cells were reseeded in 12-well plates and subjected to different treatments. For SA-β-gal staining, cells at 50 to 60% confluency were treated with Dox (50 ng/ml) for the indicated durations and then washed with ice-cold PBS and fixed for 10 min with 3% formaldehyde at room temperature. SA-β-gal staining solution (Beyotime) was prepared before use and incubated with the cells overnight at 37°C. For growth curves, 0.75 × 10 4 of either HCT116 or HT-29 cells from each group were plated in 96-well plates in triplicate and treated with 50 ng/ml doxorubicin. The cells were cultured for another 1 to 5 days and monitored by MTT assay. 49 The growth curves were generated accordingly.
Luciferase assay. For these experiments, 293T cells either untransfected or transfected with the indicated siRNAs were seeded in 24-well plates and then transfected with 100 ng of luciferase reporter plasmids plus 20 ng of pRL-TK plasmids as an internal control. Luciferase activity was measured using a dualluciferase reporter assay kit (Promega) 24 h after transfection and then normalized.
Immunofluorescence and immunohistochemistry. Immunofluorescence was performed as previously described. 43 For immunohistochemistry, xenografts were fixed in formalin, embedded in paraffin and then sliced. Antigens were retrieved using citric acid and steam and then stained with a Ki67 antibody (1 : 400, Cell Signaling Technology) and hematoxylin.
Enzyme-linked immunosorbent assay (ELISA). HCT116 cells expressing control shRNA or shBclaf1 treated with Dox for 7 days were reseeded into 6-well plates at a density of 3 × 10 6 cells per well and cultured with 1 ml fresh median for 24 h. The supernatants were then collected to measure the levels of IL-6 and IL-8 using ELISA kits purchased from Boster (Wuhan, China).
Xenografts. Animal care and protocols were approved by Animal Welfare Committee of China Agricultural University. 3 × 10 6 HT-29 cells in 100 μl PBS stably expressing either the control shRNA or shBclaf1#1 were injected subcutaneously into the left and right flanks of 6-week-old female athymic BALB/c nu/nu mice (HFK Bioscience, Beijing, China), respectively. When tumors were formed (~7 days), the mice were grouped randomly and given either PBS or 3 mg/kg Dox in PBS intraperitoneally once every 2 days for 6 times. After the treatment was stopped, the mice were allowed to grow for another 10 days before being killed under ether anesthesia by cervical dislocation. The tumors were harvested and weighed, and then were sliced for either Ki67 staining or western blot analysis.
Statistical analysis. Microsoft Excel and GraphPad Prism (La Jolla, CA, USA) were used for statistical analyses. Statistical significance was analyzed by Student's t-test and expressed as a P-value. P-values of o0.05 were considered statistically significant: *Po0.05; **Po0.01; ***Po0.001.
